On the one hand, pemetrexed plus gefitinib could prevent the resistance of gefitinib in EGFR 19del mutated NSCLC cell lines by avoiding the occurrence of the EGFR exon 20 Thr790Met mutation or epithelial to mesenchymal transition [48]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.